Press Release
atai Life Sciences Announces Results from Phase 2a Trial of PCN-101 (R-ketamine) for Treatment-Resistant Depression
NEW YORK and BERLIN, Jan. 06, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “the Company”), a clinical-stage biopharmaceutical company focused on mental health, announced that, while PCN-101 (R-ketamine) demonstrated signals of efficacy across all timepoints out to two
Press Release
atai Life Sciences Announces Results from the Kures Therapeutics Phase 1 Trial of KUR-101
-   This two-part phase 1 trial in healthy volunteers was designed to assess the safety, pharmacokinetics, and analgesic activity of KUR-101 -   KUR-101 was well tolerated and demonstrated analgesic activity in two experimental pain models -   An assessment of the respiratory impact of KUR-101 was
Press Release
atai Life Sciences Initiates Phase 2b proof-of-concept trial of RL-007 for Cognitive Impairment Associated with Schizophrenia
The phase 2b proof-of-concept trial will evaluate the novel compound, RL-007, for pro-cognitive effects in patients with Cognitive Impairment Associated with Schizophrenia (CIAS). The trial was initiated and has begun patient screening this month with first-patient-in anticipated by end-of-year.
Press Release
The atai Fellowship Fund in Psychedelic Neuroscience Announces its First Cohort at Massachusetts General Hospital
NEW YORK and BERLIN, Dec. 16, 2022 (GLOBE NEWSWIRE) -- atai Impact, the philanthropic arm of atai Life Sciences N.V. (NASDAQ: ATAI) (“atai”), today announced the first cohort of the atai Fellowship Fund in Psychedelic Neuroscience (the “Fellowship Fund”) at Massachusetts General Hospital (“MGH”)
Press Release
atai Life Sciences Strengthens Leadership Team with Appointment of Dr. Sahil V. Kirpekar as Chief Business Officer
- Dr. Kirpekar joins from Otsuka Pharmaceutical where he was Head of Business Development and Co-chair of the Global Business Development Committee - - He has spent more than 15 years building and growing organizations and businesses in the life sciences and digital health industries - - His deal
Press Release
atai Life Sciences and Massachusetts General Hospital Announce Initiation of Clinical Study Investigating Neuroplasticity Biomarkers in Treatment-Resistant Depression Patients Undergoing Ketamine Treatment
NEW YORK and BERLIN, Nov. 17, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced it has initiated a clinical study with Massachusetts General Hospital
Displaying 31 - 36 of 112